Becton Dickinson and Company
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $47.2
- Today's High:
- $48.93
- Open Price:
- $47.2
- 52W Low:
- $44.6034
- 52W High:
- $50.9255
- Prev. Close:
- $47.5
- Volume:
- 2762120
Company Statistics
- Market Cap.:
- $0
- Book Value:
- 90.442
- Revenue TTM:
- $18.81 billion
- Operating Margin TTM:
- 13.5%
- Gross Profit TTM:
- $8.61 billion
- Profit Margin:
- 8.6%
- Return on Assets TTM:
- 2.91%
- Return on Equity TTM:
- 6.56%
Company Profile
Becton Dickinson and Company had its IPO on 2020-05-21 under the ticker symbol BDXB.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Becton Dickinson and Company has a staff strength of 77,000 employees.
Stock update
Shares of Becton Dickinson and Company opened at $47.2 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $47.2 - $48.93, and closed at $48.16.
This is a +1.39% increase from the previous day's closing price.
A total volume of 2,762,120 shares were traded at the close of the day’s session.
In the last one week, shares of Becton Dickinson and Company have slipped by -3.95%.
Becton Dickinson and Company's Key Ratios
Becton Dickinson and Company has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Becton Dickinson and Company’s revenue was $18.81 billion with a gross profit of $8.61 billion and an EBITDA of $4.81 billion. The EBITDA ratio measures Becton Dickinson and Company's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Becton Dickinson and Company’s operating margin was 13.5% while its return on assets stood at 2.91% with a return of equity of 6.56%.
In Q1, Becton Dickinson and Company’s quarterly earnings growth was a positive 1.8% while revenue growth was a positive 1.5%.
Becton Dickinson and Company’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 7.6034
- PEG
Its diluted EPS in the last 12-months stands at $6.334 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Becton Dickinson and Company’s profitability.
Becton Dickinson and Company stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Becton Dickinson and Company stock pays annual dividends of $3.56 per share, indicating a yield of 5.78% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $54.39 billion
- Total Liabilities
- $7.30 billion
- Operating Cash Flow
- $0
- Capital Expenditure
- $181 million
- Dividend Payout Ratio
- 0%
Becton Dickinson and Company ended 2024 with $54.39 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $54.39 billion while shareholder equity stood at $25.69 billion.
Becton Dickinson and Company ended 2024 with $0 in deferred long-term liabilities, $7.30 billion in other current liabilities, 365000000.00 in common stock, $15.56 billion in retained earnings and $24.78 billion in goodwill. Its cash balance stood at $1.98 billion and cash and short-term investments were $1.99 billion. The company’s total short-term debt was $2,214,000,000 while long-term debt stood at $16.01 billion.
Becton Dickinson and Company’s total current assets stands at $9.59 billion while long-term investments were $0 and short-term investments were $6.00 million. Its net receivables were $2.41 billion compared to accounts payable of $0 and inventory worth $3.66 billion.
In 2024, Becton Dickinson and Company's operating cash flow was $0 while its capital expenditure stood at $181 million.
Comparatively, Becton Dickinson and Company paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $48.16
- 52-Week High
- $50.9255
- 52-Week Low
- $44.6034
- Analyst Target Price
- $
Becton Dickinson and Company stock is currently trading at $48.16 per share. It touched a 52-week high of $50.9255 and a 52-week low of $50.9255. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $49.93 and 200-day moving average was $48.64 The short ratio stood at 0.19 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Becton Dickinson and Company
Similar Industry Stocks (Medical Instruments & Supplies)
Most Active
Top Gainers
Top Losers
About
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company’s BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company’s BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.